Cited by 243COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19.

Open access

Bramante, Carolyn T., Huling, Jared D., Tignanelli, Christopher J., Buse, John B., Liebovitz, David M., Nicklas, Jacinda M., Cohen, Kenneth, Puskarich, Michael A., Belani, Hrishikesh K., Proper, Jennifer L., Siegel, Lianne K., Klatt, Nichole R., Odde, David J., Luke, Darlette G., Anderson, Blake, Karger, Amy B., Ingraham, Nicholas E., Hartman, Katrina M., Rao, Via, Hagen, Aubrey A., Patel, Barkha, Fenno, Sarah L., Avula, Nandini, Reddy, Neha V., Erickson, Spencer M., Lindberg, Sarah, Fricton, Regina, Lee, Samuel, Zaman, Adnin, Saveraid, Hanna G., Tordsen, Walker J., Pullen, Matthew F., Biros, Michelle, Sherwood, Nancy E., Thompson, Jennifer L., Boulware, David R., Murray, Thomas A.·2022·New England Journal of Medicine

DOI 10.1056/nejmoa2201662PMC PMC9945922

Open this paper in CoChat — free account

Abstract

BACKGROUND: Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. METHODS: In this phase 3, double-blind, randomized, placebo-controlled trial, we used a 2-by-3 factorial design to test the effectiveness of three repurposed drugs - metformin, ivermectin, and fluvoxamine - in preventing serious SARS-CoV-2 infection in nonhospitalized adults who had been enrolled within 3 days after a confirmed diagnosis of infection and less than 7 days after the onset of symptoms. The patients were between the ages of 30 and 85 years, and all had either overweight or obesity. The primary composite end point was hypoxemia (≤93% oxygen saturation on home oximetry), emergency department visit, hospitalization, or death. All analyses used controls who had undergone concurrent randomization and were adjusted for SARS-CoV-2 vaccination and receipt of other trial medications. RESULTS: A total of 1431 patients underwent randomization; of these patients, 1323 were included in the primary analysis. The median age of the patients was 46 years; 56% were female (6% of whom were pregnant), and 52% had been vaccinated. The adjusted odds ratio for a primary event was 0.84 (95% confidence interval [CI], 0.66 to 1.09; P = 0.19) with metformin, 1.05 (95% CI, 0.76 to 1.45; P = 0.78) with ivermectin, and 0.94 (95% CI, 0.66 to 1.36; P = 0.75) with fluvoxamine. In prespecified secondary analyses, the adjusted odds ratio for emergency department visit, hospitalization, or death was 0.58 (95% CI, 0.35 to 0.94) with metformin, 1.39 (95% CI, 0.72 to 2.69) with ivermectin, and 1.17 (95% CI, 0.57 to 2.40) with fluvoxamine. The adjusted odds ratio for hospitalization or death was 0.47 (95% CI, 0.20 to 1.11) with metformin, 0.73 (95% CI, 0.19 to 2.77) with ivermectin, and 1.11 (95% CI, 0.33 to 3.76) with fluvoxamine. CONCLUSIONS: None of the three medications that were evaluated prevented the occurrence of hypoxemia, an emergency department visit, hospitalization, or death associated with Covid-19. (Funded by the Parsemus Foundation and others; COVID-OUT ClinicalTrials.gov number, NCT04510194.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2201662

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial
Reis, G., Silva, E. A. D. S. M., Silva, D. C. M., Thabane, L., Milagres, A. C., Ferreira, T. S., dos Santos, C. V. Q., Neto, A. D. D. F., Callegari, E. D., Savassi, L. C. M., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100142 · Cited by 65
Retracted
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
(2013) · JAMA · doi:10.1001/jama.2013.281053 · Cited by 30,732
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Untitled work
(2020) · PubMed · Cited by 2,642
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118542 · Cited by 2,323
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016638 · Cited by 1,349
Self-citation
Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study
Cariou, B., Hadjadj, S., Wargny, M., Pichelin, M., Al‐Salameh, A., Allix, I., Amadou, C., Arnault, G., Baudoux, F., Bauduceau, B., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05180-x · Cited by 834
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19
Skipper, C. P., Pastick, K. A., Engen, N. W., Bangdiwala, A. S., Abassi, M., Lofgren, S. M., Williams, D. A., Okafor, E. C., Pullen, M. F., Nicol, M. R., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-4207 · Cited by 538
Self-citation
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial
Lenze, E. J., Mattar, C., Zorumski, C. F., Stevens, A., Schweiger, J., Nicol, G. E., Miller, J. P., Yang, L., Yingling, M., Avidan, M. S., et al. (2020) · JAMA · doi:10.1001/jama.2020.22760 · Cited by 495

Flagged first, then by citations

Show all 50 references

1 of the 50 references couldn’t be matched to a known paper.

Sorted by citations

Metformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 791
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
Bramante, C. T., Buse, J. B., Liebovitz, D., Nicklas, J. M., Puskarich, M. A., Cohen, K., Belani, H., Anderson, B., Huling, J. D., Tignanelli, C. J., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00299-2 · Cited by 230
Self-citation
Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19
Lightner, A. L., Sengupta, V., Qian, S., Ransom, J. T., Suzuki, S., Park, D. J., Melson, T. I., Williams, B. P., Walsh, J. J., & Awili, M. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.06.024 · Cited by 166
Signaling pathways in macrophages: molecular mechanisms and therapeutic targets
Li, M., Wang, M., Wen, Y., Zhang, H., Zhao, G., & Gao, Q. (2023) · MedComm · doi:10.1002/mco2.349 · Cited by 157
Therapeutics for COVID-19
Toussi, S. S., Hammond, J., Gerstenberger, B. S., & Anderson, A. S. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01356-4 · Cited by 113
Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study
Du, Y., Zhu, Y., Zhou, Y., Ding, J., & Liu, J. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00108-w · Cited by 84
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial
Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Slandzicki, A. J., Lim, S. C., Cohen, J., Kavtaradze, D., Amon, A. P., Gabriel, A., et al. (2023) · JAMA · doi:10.1001/jama.2023.1650 · Cited by 79
Self-citation
Cardiovascular disease as part of Long COVID: a systematic review
Tsampasian, V., Bäck, M., Bernardi, M., Cavarretta, E., Dębski, M., Gati, S., Hansen, D., Kränkel, N., Koskinas, K. C., Niebauer, J., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae070 · Cited by 84
Quantum machine learning framework for virtual screening in drug discovery: a prospective quantum advantage
Mensa, S., Sahin, E., Tacchino, F., Barkoutsos, P. K., & Tavernelli, I. (2023) · Machine Learning Science and Technology · doi:10.1088/2632-2153/acb900 · Cited by 91
An overview on the treatments and prevention against COVID-19
Panahi, Y., Gorabi, A. M., Talaei, S., Beiraghdar, F., Akbarzadeh, A., Tarhriz, V., & Mellatyar, H. (2023) · Virology Journal · doi:10.1186/s12985-023-01973-9 · Cited by 73
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19
McCarthy, M. W., Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Felker, G. M., Jayaweera, D. T., Sulkowski, M., Gentile, N., Bramante, C. T., et al. (2023) · JAMA · doi:10.1001/jama.2022.24100 · Cited by 62
Self-citation
Metformin targets mitochondrial complex I to lower blood glucose levels
Reczek, C. R., Chakrabarty, R. P., D’Alessandro, K. B., Sebo, Z. L., Grant, R. A., Gao, P., Budinger, G. R. S., & Chandel, N. S. (2024) · Science Advances · doi:10.1126/sciadv.ads5466 · Cited by 64
Metformin: Past, Present, and Future
Chaudhary, S., & Kulkarni, A. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01539-1 · Cited by 64
COVID‐19 immunopathology: From acute diseases to chronic sequelae
Arish, M., Qian, W. G., Narasimhan, H., & Sun, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28122 · Cited by 55
Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19
Bramante, C. T., Beckman, K. B., Mehta, T., Karger, A. B., Odde, D. J., Tignanelli, C. J., Buse, J. B., Johnson, D. M., Watson, R. H. B., Daniel, J. J., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae159 · Cited by 63
Self-citation
COVID-19 therapeutics
Focosi, D., Franchini, M., Maggi, F., & Shoham, S. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00119-23 · Cited by 51
Time to Stop Using Ineffective Covid-19 Drugs
Karim, S. S. A., & Devnarain, N. (2022) · New England Journal of Medicine · doi:10.1056/nejme2209017 · Cited by 41
Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19
Zhu, B., Wei, X., Narasimhan, H., Qian, W. G., Zhang, R., Cheon, I. S., Wu, Y., Li, C., Jones, R. G., Kaplan, M. H., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adf0348 · Cited by 39
Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases
Perakakis, N., Harb, H., Hale, B. G., Varga, Z., Steenblock, C., Kanczkowski, W., Alexaki, V. I., Ludwig, B., Mirtschink, P., Solimena, M., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00154-7 · Cited by 39
Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review
Fernández‐de‐las‐Peñas, C., Torres‐Macho, J., Catahay, J. A., Macasaet, R., Velasco, J. V., Macapagal, S. C., Caldararo, M. D., Henry, B. M., Lippi, G., Franco‐Moreno, A., et al. (2023) · Infection · doi:10.1007/s15010-023-02154-0 · Cited by 34
Pathogenic mechanisms of cardiovascular damage in COVID-19
Shao, H., & Yin, R. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00855-2 · Cited by 44
Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19
Reis, G., Silva, E. A. D. S. M., Silva, D. C. M., Thabane, L., Campos, V. H. D. S., Ferreira, T. S., dos Santos, C. V. Q., Nogueira, A. M. R., Almeida, A. P. F. G., Savassi, L. C. M., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3305 · Cited by 36
Self-citation
Computational Approaches to Drug Repurposing: Methods, Challenges, and Opportunities
Cousins, H. C., Nayar, G., & Altman, R. B. (2024) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-110123-025333 · Cited by 41
Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-upPreprint
Bramante, C. T., Buse, J. B., Liebovitz, D., Nicklas, J. M., Puskarich, M. A., Cohen, K., Belani, H., Anderson, B., Huling, J. D., Tignanelli, C. J., et al. (2022) · medRxiv · doi:10.1101/2022.12.21.22283753 · Cited by 35
Self-citation
Metformin, a biological and synthetic overview
Hernández‐Velázquez, E. D., Betancourt, C. A., Alonso‐Castro, Á. J., Ortíz‐Alvarado, R., López, J. A., Carmen, V. M., & Solorio‐Alvarado, C. R. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129241 · Cited by 36
Metformin in Antiviral Therapy: Evidence and Perspectives
Halabitska, I., Petakh, P., Lushchak, O. V., Kamyshna, I. I., Oksenych, V., & Kamyshnyi, O. (2024) · Viruses · doi:10.3390/v16121938 · Cited by 37
Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis
Deng, J., Rayner, D. G., Ramaraju, H. B., Abbas, U., Garcia, C., Heybati, K., Zhou, F., Huang, E., Park, Y., & Moskalyk, M. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.01.010 · Cited by 36
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19
Stewart, T. G., Rebolledo, P. A., Mourad, A., Lindsell, C. J., Boulware, D. R., McCarthy, M. W., Thicklin, F., del Sol, I. T. G., Bramante, C. T., Lenert, L. A., et al. (2023) · JAMA · doi:10.1001/jama.2023.23363 · Cited by 31
Self-citation
Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19
Sidky, H., Hansen, K., Girvin, A. T., Hotaling, N. A., Michael, S. G., Gersing, K. R., & Sahner, D. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.12.045 · Cited by 29
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Hayward, G., Yu, L.-M., Little, P., Gbinigie, O., Shanyinde, M., Harris, V., Dorward, J., Saville, B. R., Berry, N., Evans, P. H., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106130 · Cited by 31
COVID-19 and metabolic syndrome
Sendur, S., Oğuz, S. H., & Ünlütürk, U. (2023) · Best practice & research. Clinical endocrinology & metabolism · doi:10.1016/j.beem.2023.101753 · Cited by 41
Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19
Hoertel, N., Rico, M. S., Kornhuber, J., Gulbins, E., Reiersen, A. M., Lenze, E. J., Fritz, B. A., Jalali, F., Mills, E. J., Cougoule, C., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195882 · Cited by 29
Self-citation
Overview of the potential use of fluvoxamine for COVID-19 and long COVID
Hashimoto, K. (2023) · Discover Mental Health · doi:10.1007/s44192-023-00036-3 · Cited by 25
Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19
Boulware, D. R., Lindsell, C. J., Stewart, T. G., Hernandez, A. F., Collins, S. P., McCarthy, M. W., Jayaweera, D. T., Gentile, N., Castro, M., Sulkowski, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2209421 · Cited by 26
Self-citation
Targeting AMP-activated protein kinase in sepsis
Yumoto, T., & Coopersmith, C. M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1452993 · Cited by 25
Outpatient randomized controlled trials to reduce COVID‐19 hospitalization: Systematic review and meta‐analysis
Sullivan, D. J., Focosi, D., Hanley, D. F., Cruciani, M., Franchini, M., Ou, J., Casadevall, A., & Paneth, N. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29310 · Cited by 35
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
Haddad, F., Dokmak, G., & Karaman, R. (2022) · Life · doi:10.3390/life12111758 · Cited by 25
Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model
Péricat, D., Leon‐Icaza, S. A., Rico, M. S., Mühle, C., Zoicas, I., Schumacher, F., Planès, R., Mazars, R., Gros, G., Carpinteiro, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113623 · Cited by 26
Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment?
Schreiber, A., & Ludwig, S. (2025) · Antiviral Research · doi:10.1016/j.antiviral.2025.106101 · Cited by 23
SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids
Izumi, Y., Reiersen, A. M., Lenze, E. J., Mennerick, S. J., & Zorumski, C. F. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02343-3 · Cited by 22
Emerging uncertainty on the anti-aging potential of metformin
Keys, M. T., Hallas, J., Miller, R. A., Suissa, S., & Christensen, K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102817 · Cited by 24
Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients
Takayama, S., Namiki, T., Arita, R., Ono, R., Kikuchi, A., Ohsawa, M., Saito, N., Suzuki, S., Nakae, H., Kobayashi, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1008946 · Cited by 22
Metformin is associated with reduced COVID-19 severity in patients with prediabetes
Chan, L., Casiraghi, E., Laraway, B. J., Coleman, B., Blau, H., Zaman, A., Harris, N. L., Wilkins, K. J., Antony, B., Gargano, M. A., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110157 · Cited by 18
Self-citation
Metformin for Treatment of Acute COVID-19: Systematic Review of Clinical Trial Data Against SARS-CoV-2
Erickson, S. M., Fenno, S. L., Barzilai, N., Kuchel, G. A., Bartley, J. M., Justice, J. N., Buse, J. B., & Bramante, C. T. (2023) · Diabetes Care · doi:10.2337/dc22-2539 · Cited by 19
Self-citation
The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis
Singh, S., Boyd, S., Schilling, W. H., Watson, J. A., Mukaka, M., & White, N. J. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae045 · Cited by 21
SARS-CoV-2 infection is associated with intestinal permeability, systemic inflammation, and microbial dysbiosis in hospitalized patients
Basting, C. M., Langat, R., Broedlow, C. A., Guerrero, C. R., Bold, T. D., Bailey, M. A., Velez, A., Schroeder, T. A., Short-Miller, J. C., Cromarty, R. T., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00680-24 · Cited by 22
Self-citation
The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial
Reiersen, A. M., Mattar, C., Ignacio, R. B., Boulware, D. R., Lee, T. C., Hess, R., Lankowski, A. J., McDonald, E. G., Miller, J. P., Powderly, W. G., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad419 · Cited by 19
Self-citation
Old drug, new tricks: the utility of metformin in infection and vaccination responses to influenza and SARS-CoV-2 in older adults
Martin, D. E., Cadar, A. N., & Bartley, J. M. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1272336 · Cited by 21
Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses
Meyerowitz, E. A., & Li, Y. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad685 · Cited by 18
Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis
Ibrahim, S., Siemieniuk, R. A. C., Oliveros, M. J., Islam, N., Martinez, J. P. D., Izcovich, A., Qasim, A., Zhao, Y., Zaror, C., Yao, L., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081165 · Cited by 20
Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis
Cheema, H. A., Jafar, U., Elrashedy, A. A., Shahid, A., Awan, R. U., Ehsan, M. T., Ayyan, M., & Sahra, S. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.10.012 · Cited by 16
Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection
Alabsi, S. M., Dhole, A., Hozayen, S. M., & Chapman, S. A. (2023) · Microorganisms · doi:10.3390/microorganisms11030612 · Cited by 16
A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications
Prasanth, M. I., Wannigama, D. L., Reiersen, A. M., Thitilertdecha, P., Prasansuklab, A., Tencomnao, T., Brimson, S. J., & Brimson, J. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-64260-9 · Cited by 16
COVID-19 Molecular Pathophysiology: Acetylation of Repurposing Drugs
Lee, J., Kanwar, B. A., Khattak, A., Balentine, J., Nguyen, N. H., Kast, R. E., Lee, C. J., Bourbeau, J., Altschuler, E. L., Sergi, C. M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113260 · Cited by 18
Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)
Siripongboonsitti, T., Ungtrakul, T., Tawinprai, K., Nimmol, T., Buttakosa, M., Sornsamdang, G., Jarrusrojwuttikul, T., Silapant, P., & Mahanonda, N. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.06.018 · Cited by 15
Ivermectin for treatment of COVID-19: A systematic review and meta-analysis
Song, Z., Shi, S., & Zhang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27647 · Cited by 15
Bile acids and coronavirus disease 2019
Huang, X., Liu, X., & Li, Z. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.011 · Cited by 15
Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program
Johnson, S., Abedian, S., Stürmer‎, T., Huling, J. D., Lewis, C., V, Buse, J. B., Brosnahan, S. B., Mudumbi, P. C., Erlandson, K. M., McComsey, G. A., et al. (2024) · Diabetes Care · doi:10.2337/dca24-0032 · Cited by 14
Self-citation
Sertraline modulates hippocampal plasticity via sigma 1 receptors, cellular stress and neurosteroids
Izumi, Y., Reiersen, A. M., Lenze, E. J., Mennerick, S. J., & Zorumski, C. F. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03185-3 · Cited by 14
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial
Boulware, D. R., Murray, T. A., Proper, J. L., Tignanelli, C. J., Buse, J. B., Liebovitz, D., Nicklas, J. M., Cohen, K., Puskarich, M. A., Belani, H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac772 · Cited by 14
Self-citation
Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study
Kirenga, B., Mugenyi, L., Rico, M. S., Bosa, H. K., Muttamba, W., Mugume, R., Mwesigwa, E., Kalimo, E., Nyombi, V., Segawa, I., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02004-3 · Cited by 15
Outpatient regimens to reduce COVID-19 hospitalisations: a systematic review and meta-analysis of randomized controlled trialsPreprint
Sullivan, D. J., Focosi, D., Hanley, D. F., Cruciani, M., Franchini, M., Ou, J., Casadevall, A., & Paneth, N. (2022) · medRxiv · doi:10.1101/2022.05.24.22275478 · Cited by 14
Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical TrialPreprint
Bramante, C. T., Beckman, K. B., Mehta, T., Karger, A. B., Odde, D. J., Tignanelli, C. J., Buse, J. B., Johnson, D. M., Watson, R. H. B., Daniel, J. J., et al. (2023) · medRxiv · doi:10.1101/2023.06.06.23290989 · Cited by 14
Self-citation
Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years
Remuzzi, G., Schiaffino, S., Santoro, M. G., FitzGerald, G. A., Melino, G., & Patrono, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.987816 · Cited by 16
Dry powder formulation of azithromycin for COVID-19 therapeutics
Chan, S. H. Y., Sheikh, K., Zariwala, M. G., & Somavarapu, S. (2023) · Journal of Microencapsulation · doi:10.1080/02652048.2023.2175924 · Cited by 13
Experimental drugs in randomized controlled trials for long-COVID: what’s in the pipeline? A systematic and critical review
Yong, S. J., Halim, A., Halim, M., Ming, L. C., Goh, K. W., Alfaresi, M. S., Alshehail, B. M., Fares, M. A. A., Alissa, M., Sulaiman, T., et al. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2242773 · Cited by 12
Evaluating fluvoxamine for the outpatient treatment of COVID‐19: A systematic review and meta‐analysis
Deng, J., Moskalyk, M., Zuo, Q., Garcia, M. C., Abbas, U., Ramaraju, H. B., Rayner, D. G., Park, Y., Heybati, K., Zhou, F., et al. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2501 · Cited by 12
Northwestern University resource and education development initiatives to advance collaborative artificial intelligence across the learning health system
Luo, Y., Mao, C., Sanchez-Pinto, L. N., Ahmad, F. S., Naidech, A. M., Rasmussen, L. V., Pacheco, J. A., Schneider, D., Mithal, L. B., Dresden, S. M., et al. (2024) · Learning Health Systems · doi:10.1002/lrh2.10417 · Cited by 13
Self-citation
Antidepressant-induced membrane trafficking regulates blood-brain barrier permeability
Du, W., Chen, H., Gróf, I., Lemaitre, L., Bocsik, A., Perdyan, A., Mieczkowski, J., Deli, M. A., Hortobágyi, T., Wan, Q., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02626-1 · Cited by 14
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)
Jittamala, P., Boyd, S., Schilling, W. H., Watson, J. A., Ngamprasertchai, T., Siripoon, T., Luvira, V., Batty, E. M., Wongnak, P., Esper, L., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.103036 · Cited by 12
COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development
Bostanghadiri, N., Ziaeefar, P., Mofrad, M. G., Yousefzadeh, P., Hashemi, A., & Darban‐Sarokhalil, D. (2023) · BioMed Research International · doi:10.1155/2023/1879554 · Cited by 17
The impact of gut microbiome and diet on post-acute sequelae of SARS-CoV-2 infection
Reyes, Z., Stovall, M. C., Punyamurthula, S., Longo, M. T., Maraganore, D. M., & Solch-Ottaiano, R. J. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123295 · Cited by 13
Persistent immune dysregulation and metabolic alterations following SARS-CoV-2 infectionPreprint
Lage, S. L., Bricker, K. M., Rocco, J. M., Rupert, A. W., Donovan, F. X., Abramzon, Y. A., Chandrasekharappa, S. C., McNinch, C. M., Cook, L., Amaral, E. P., et al. (2025) · medRxiv · doi:10.1101/2025.04.16.25325949 · Cited by 12
Extensive therapeutic effects, underlying molecular mechanisms and disease treatment prediction of Metformin: a systematic review
Geng, Y., Wang, Z., Xu, X., Sun, X., Dong, X., Luo, Y., & Sun, X. (2023) · Translational research · doi:10.1016/j.trsl.2023.08.001 · Cited by 13
Associations between COVID-19 infection experiences and mental health problems among Chinese adults: A large cross-section study
Zhang, S., Liu, Q., Yang, F., Zhang, J., Fu, Y., Zhu, Z., Guo, J., Li, X., & Yang, L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.08.080 · Cited by 13
The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials
Zhou, Q., Zhao, G., Pan, Y., Zhang, Y., & Ni, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300512 · Cited by 11
Unlocking the potential of signature-based drug repurposing for anticancer drug discovery
Biswal, S., & Mallick, B. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110150 · Cited by 12
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
Bramante, C. T., Buse, J. B., & Boulware, D. R. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2212542 · Cited by 11
Self-citation
Metformin as a potential treatment for COVID-19
McCarthy, M. W. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2215385 · Cited by 11
Long COVID and cardiovascular disease: a prospective cohort study
Lawson, C. A., Moss, A. J., Arnold, J. R., Bagot, C. N., Banerjee, A., Berry, C., Greenwood, J. P., Hughes, A. D., Khunti, K. K., Mills, N. L., et al. (2024) · Open Heart · doi:10.1136/openhrt-2024-002662 · Cited by 10
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity
Wimalawansa, S. J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34691 · Cited by 11
COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023
Yavuz, S. Ş. (2023) · Infectious Diseases and Clinical Microbiology · doi:10.36519/idcm.2023.251 · Cited by 10
Type 1 Diabetes and COVID-19: A Literature Review and Possible Management
Kashfi, K., Anbardar, N., Asadipooya, A., & Asadipooya, K. (2023) · Intern J Endocrinol Metab · doi:10.5812/ijem-139768 · Cited by 10
Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials
Vatvani, A. D., Kurniawan, A., & Hariyanto, T. I. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231162243 · Cited by 10
Clinical development of antivirals against SARS-CoV-2 and its variants
Lan, Q., Yan, Y., Zhang, G., Xia, S., Zhou, J., Lu, L., & Jiang, S. (2023) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2023.100208 · Cited by 9
Plant Extracts and SARS-CoV-2: Research and Applications
Heleno, S. A., Carocho, M., Reis, F. S., Pires, T. C. S. P., Pintado, M., Ferreira, I. C. F. R., & Barros, L. (2023) · Life · doi:10.3390/life13020386 · Cited by 10
Anthracyclines inhibit SARS-CoV-2 infection
Wang, Z., Pan, Q., Ma, L., Zhao, J., McIntosh, F. A., Liu, Z., Ding, S., Lin, R., Cen, S., Finzi, A., et al. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199164 · Cited by 10
A Dual Pharmacological Strategy against COVID-19: The Therapeutic Potential of Metformin and Atorvastatin
Jesús‐González, L. A. D., del Ángel, R. M., Palacios-Rápalo, S. N., Cordero‐Rivera, C. D., Rodríguez-Carlos, A., Trujillo-Páez, J. V., Farfán-Morales, C. N., Osuna‐Ramos, J. F., Reyes-Ruíz, J. M., Rivas-Santiago, B. T., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12020383 · Cited by 9
Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer’s, and diabetes
Malar, D. S., Verma, K., Prasanth, M. I., Tencomnao, T., & Brimson, J. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-55013-9 · Cited by 9
Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution
Borovčanin, M., Vesić, K., Balcıoğlu, Y. H., & Mijailović, N. R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1052710 · Cited by 9
Timing of Antiretroviral Therapy in Cryptococcal Meningitis: What We Can (and Cannot) Learn From Observational Data
Boulware, D. R., & Jarvis, J. N. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad123 · Cited by 9
Self-citation
CROI 2025: Acute and Postacute COVID-19
Antar, A. A. R., & Peluso, M. J. (2025) · Topics in antiviral medicine · doi:10.68040/2025333.555568 · Cited by 9
Lack of Benefit of Fluvoxamine for COVID-19
Bhimraj, A., & Gallagher, J. C. (2023) · JAMA · doi:10.1001/jama.2022.23954 · Cited by 9
The impact of ivermectin on COVID-19 outcomes: a systematic review and meta-analysis
Yengu, N. S., Raheem, A., Pons, A. G., Ho, W. L., Ali, S. M. S., Haseeb, A., Ahmad, T. K. F., & Mustafa, M. S. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002762 · Cited by 8
Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: A systematic review and meta-analysis of 12 randomized controlled trials with 7,035 participants
Hernández, A. V., Liu, A., Roman, Y. M., Burela, P. A., Pasupuleti, V., Thota, P., Carranza-Tamayo, C. O., Palacios, M. R. R., Benites-Zapata, V. A., Piscoya, A., et al. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107248 · Cited by 10
Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19
Anar, M. A., Foroughi, E., Sohrabi, E., Peiravi, S., Tavakoli, Y., Khouzani, M. K., Behshood, P., Shamshiri, M., Faridzadeh, A., Keylani, K., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1036093 · Cited by 11
COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State
Chamie-Quintero, J. J., Hibberd, J. A., & Scheim, D. E. (2023) · Cureus · doi:10.7759/cureus.43168 · Cited by 9
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical TrialPreprint
McCarthy, M. W., Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Felker, G. M., Jayaweera, D. T., Sulkowski, M., Gentile, N., Bramante, C. T., et al. (2022) · medRxiv · doi:10.1101/2022.10.17.22281178 · Cited by 8
Self-citation
Metformin on Time to Sustained Recovery in Adults with COVID-19: The ACTIV-6 Randomized Clinical Trial
Bramante, C. T., Stewart, T. G., Boulware, D. R., McCarthy, M. W., Gao, Y., Rothman, R. L., Mourad, A., Thicklin, F., Cohen, J. B., Garcia del Sol, I. T., et al. (2025) · doi:10.1101/2025.01.13.25320485 · Cited by 8
Self-citation
Metformin use before COVID-19 vaccination and the risks of COVID-19 incidence, medical utilization, and all-cause mortality in patients with type 2 diabetes mellitus
Yen, F., Wang, S., Lin, S., & Wei, J. C. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110692 · Cited by 7

Authors: Bramante, C. T., Huling, J. D., Tignanelli, C. J., Buse, J. B., Liebovitz, D. M., Nicklas, J. M., Cohen, K., Puskarich, M. A., Belani, H. K., Proper, J. L., Siegel, L. K., Klatt, N. R., Odde, D. J., Luke, D. G., Anderson, B., Karger, A. B., Ingraham, N. E., Hartman, K. M., Rao, V., Hagen, A. A., Patel, B., Fenno, S. L., Avula, N., Reddy, N. V., Erickson, S. M., Lindberg, S., Fricton, R., Lee, S., Zaman, A., Saveraid, H. G., Tordsen, W. J., Pullen, M. F., Biros, M., Sherwood, N. E., Thompson, J. L., Boulware, D. R., & Murray, T. A.
Affiliations: University of Minnesota (US)
University of North Carolina at Chapel Hill (US)
Northwestern University (US)
ORCID: Bramante, Carolyn T.
Huling, Jared D.
Tignanelli, Christopher J.
Buse, John B.
Liebovitz, David M.
Nicklas, Jacinda M.
Puskarich, Michael A.
Belani, Hrishikesh K.
Proper, Jennifer L.
Siegel, Lianne K.
Klatt, Nichole R.
Odde, David J.
Anderson, Blake
Karger, Amy B.
Ingraham, Nicholas E.
Hartman, Katrina M.
Avula, Nandini
Reddy, Neha V.
Erickson, Spencer M.
Lindberg, Sarah
Lee, Samuel
Zaman, Adnin
Pullen, Matthew F.
Biros, Michelle
Sherwood, Nancy E.
Boulware, David R.
Murray, Thomas A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2022-08-18
Volume: 387
Issue: 7
Pages: 599-610
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2201662
PMC: PMC9945922
OpenAlex: W4292148078
Cited by: 242
References: 50
Citations by year: 2026: 19 · 2025: 31 · 2024: 63 · 2023: 94 · 2022: 35
FWCI: 27.26
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: UnitedHealth Group Foundation
Fast Grants
National Center for Advancing Translational Sciences (KL2TR002492, UL1TR002494)
National Institute of Diabetes and Digestive and Kidney Diseases (DK124654-01A1)
Rainwater Charitable Foundation
The Parsemus Foundation
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
Keywords: COVID-19 pandemic, SARS-CoV-2, metformin, ivermectin, fluvoxamine, drug repurposing, antiviral therapy, disease progression prevention, hypoxemia, hospitalization, mortality, obesity, overweight, emergency department visits, COVID-19 vaccination
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, COVID-19 Drug Treatment, Adult, Aged, Aged, 80 and over, Hypoxia, Double-Blind Method, Female, Humans, Ivermectin, Male, Metformin, Middle Aged, Obesity, Pregnancy, Pregnancy Complications, Infectious, Fluvoxamine, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks